Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00721201 | Glucocorticoid Receptor Antagonism in Subclinical Cushings | PHASE1 | COMPLETED | 6 | — | — | Nov 1, 2008 | Mar 1, 2010 | Jan 26, 2021 | 1 | United Kingdom |
| Name | Type | Description |
|---|---|---|
| Mifepristone | DRUG | Use of mifepristone 200mg bd for 8 weeks |
Inclusion Criteria: * Patients will be eligible for inclusion if: they are males and over 18, lack clinical features classically associated with Cushing's syndrome; have evidence of excess circulating cortisol Exclusion Criteria: * Evidence of local or systemic malignancy; overt Cushing's syndrom...